LeeSSchwartzbergMD

Oncology • Reno, NV

Professor, Medicine-Hematology, University of Tennessee Health Science Center College of Medicine

Join to view full profile

Dr. Schwartzberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schwartzberg's full profile

Already have an account?

Office
75 Pringle Way
Ste 801
Reno, NV 89502
Phone+1 775-982-5000

Fax+1 775-982-2821

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1983 - 1987
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1981 - 1983
New York Medical CollegeClass of 1980

Certifications & Licensure

NV State Medical License 2021 - 2025
AR State Medical License 2002 - 2023
MS State Medical License 1989 - 2022
TN State Medical License 1987 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Memphis Magazine: Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2009-2012
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma Start of enrollment: 2001 Nov 01
Completed
Phase 2
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2005 Jun 01
Completed
Phase 1
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy Start of enrollment: 2007 Jun 01
Completed
Phase 2
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer Start of enrollment: 2008 Aug 01
Completed
Phase 2
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
Completed
Phase 2
A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors Start of enrollment: 2011 Mar 01
Unknown status
Phase 1
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2012 May 01
Unknown status
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Evaluation of a Mobile App to Promote Social Support for Oncology Patients Start of enrollment: 2020 Mar 12
Completed
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

66 citations
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negati...
William J. Gradishar, Virginia G. Kaklamani, T. P. Sahoo, Dasappa Lokanatha, Vinod Raina
European Journal of Cancer. 2013-01-01
23 citations
Chemotherapy-induced nausea and vomiting: state of the art in 2006.
Lee S. Schwartzberg
The Journal of Supportive Oncology. 2006-02-01
44 citations
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.
Gisoo Barnes, Ashutosh Pathak, Lee S. Schwartzberg
Cancer Medicine. 2014-12-01

Abstracts/Posters

Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
Lee S. Schwartzberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemothera...
2019 ASCO Annual Meeting - 6/1/2019
Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.
2019 ASCO Annual Meeting - 6/1/2019
7th Community Oncology Conference
Global Academy for Medical Education (Elsevier), Las Vegas, Nevada - 3/30/2012

Press Mentions

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)November 4th, 2024
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)November 4th, 2024
Freenome Adds Renown Health as Partner for the Sanderson StudyMarch 28th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member